Literature DB >> 15806307

Effects of met-enkephalin on cell proliferation in different models of adrenocortical-cell growth.

Ludwik K Malendowicz1, Piera Rebuffat, Cinzia Tortorella, Gastone G Nussdorfer, Agnieszka Ziolkowska, Anna Hochol.   

Abstract

Met-enkephalin (met-Enk) is an opioid peptide that acts via three main subtypes of receptors referred to as mu (mu)-, delta (delta)- and zeta (zeta)-receptor. While the first two receptor subtypes mediate the classic opioid effects of met-Enk, zeta-receptors are reported to be involved in the non-opioid actions of the peptide, i.e. the inhibitory effect on the cell growth. Despite the fact that met-Enk is known to regulate the function of the hypothalamic-pituitary-adrenal axis acting on both its central and peripheral branches, none is known on the effects of met-Enk on adrenal growth. Hence, we have investigated the effects of met-Enk and its receptor agonists and antagonists on cell proliferation in three different models of rat adrenal growth: i) immature adrenal cortex, ii) regenerating adrenal cortex and iii) primary cultures of adrenocortical cells. In in vivo experiments, rats were given subcutaneous injections of 1 nmol/100 g of the peptides 28, 16 and 4 h before the sacrifice, and proliferative activity was assessed by counting the number of metaphase-arrested cells (after vincristine administration). In in vitro studies, cultured adrenocortical cells were exposed for 48 h to the peptides at a concentration of 10(-6) M, and proliferative activity was measured by the EZ4U method. The blockade of mu- and delta-receptors raised proliferative activity in immature adrenals and decreased it in regenerating glands, and the effects were reversed by mu- and delta-receptor agonists. Naltrexone-induced blockade of all met-Enk receptor subtypes decreased proliferative activity in immature adrenal and raised it in regenerating glands. The exposure to either mu- or delta-receptor agonists and antagonists evoked doubtful or no effects on the proliferative activity of cultured adrenocortical cells. In contrast, met-Enk exerted a marked antiproliferogenic effect that was reversed by naltrexone. Taken together, these findings allow us to draw the following conclusions: i) mu- and delta-receptor activation inhibits the growth of immature adrenals, stimulates adrenal regeneration, and does not affect proliferation of cultured adrenocortical cells; ii) zeta-receptors mediate the growth inhibitory effect of met-Enk on both regenerating adrenals and cultured adrenocortical cells, but unexpectedly their activation stimulates the growth of immature gland; and iii) the effects of mu- and delta-receptor activation in in vivo experiments are probably mediated by extra-adrenal indirect mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806307

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

Review 1.  Current research on opioid receptor function.

Authors:  Yuan Feng; Xiaozhou He; Yilin Yang; Dongman Chao; Lawrence H Lazarus; Ying Xia
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

2.  The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.

Authors:  Fan Cheng; Patricia J McLaughlin; Michael F Verderame; Ian S Zagon
Journal:  Mol Biol Cell       Date:  2008-10-15       Impact factor: 4.138

3.  IL18 signaling promotes homing of mature Tregs into the thymus.

Authors:  Cristina Peligero-Cruz; Tal Givony; Arnau Sebé-Pedrós; Jan Dobeš; Noam Kadouri; Shir Nevo; Francesco Roncato; Ronen Alon; Yael Goldfarb; Jakub Abramson
Journal:  Elife       Date:  2020-07-20       Impact factor: 8.140

4.  Expression and Localization of Opioid Receptors in Male Germ Cells and the Implication for Mouse Spermatogenesis.

Authors:  Haizea Estomba; Iraia Muñoa-Hoyos; Marta Gianzo; Itziar Urizar-Arenaza; Luis Casis; Jon Irazusta; Nerea Subirán
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.